CGM
Evidation Health is teaming up with Tidepool to launch a connected device-powered study of nocturnal hypoglycemic events in people with Type 1 diabetes.
Shortly after launching its integrated continuous glucose monitoring system, Dexcom announced a 42 percent increase in year-over-year sales during its Q2 earnings call.
Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues.
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players.
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States.
Glucose-monitoring contact lenses have been a continuing area of interest from developers all over the world.
Dexcom started out the year strong following the FDA clearance of its integrated continuous glucose monitor the G6.
Forty mph winds pelted cold rain against the runners as they approached the Boston Marathon’s infamous Heartbreak Hill.
Yesterday Dexcom got the nod from the FDA to market their Dexcom G6, an integrated continuous glucose monitoring system (iCGM), making it the first interoperable CGM to get the designation.
Medtronic has finally received FDA clearance for Guardian Connect, its smartphone-connected standalone CGM for patients who use multiple daily injections (MDI) for their insulin.